The main component of Lipinex is fenofibrate, which can significantly reduce the level of serum triglycerides by about 40%-56%, and can better reduce the level of total cholesterol, and can also increase the level of HDL cholesterol accordingly. Lipinzhi can improve the effect of fibrinolytic activity in the body, and has a certain effect of reducing fibrinogen and blood uric acid, which is beneficial to prevent the occurrence and development of atherosclerosis. In clinical practice, it is mainly used for the treatment of hypertriglyceridemia and mixed hyperlipidemia, but it is contraindicated in pregnant and lactating women, and is also used with caution in patients with hepatic and renal insufficiency. Common adverse reactions include transient, transient elevation of hepatic transaminases and occasionally increased levels of urea nitrogen and creatinine, but these abnormalities often return to normal after discontinuation of the drug.